Skip to main content

Fiscal Wizard · Single-issue tearsheet

LH / Aug 13, 2026 Run #13782

LH

Labcorp Holdings Inc.

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Composite verdict

B 70.8 / 100
Bullish setup · Reversal 22 drivers · 3 gates blocking
  • 52-Week Proximity
  • Aroon Oscillator
  • Trendline Break
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 2nd of 11 in Diagnostics & Research

rescore-sweep
Technical synthesisRegime: volatile uptrend
Bull 100%Evidence: High · 25 signals0% Bear
Momentum Bullish 97Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -62%
Asset value $106.29Earnings power value $94.22Price $323.48

Priced above its no-growth earnings power value ($94.22/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

41.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Inventory Turnover 100
Margin of Safety 0
Forward P/E 85
OCF to Net Income 0
EV/Sales 79
Earnings Yield 3

Technicals Bullish

100.0 / 100

Bullish setup leads (52-Week Proximity, Aroon Oscillator, Trendline Break); bears gated by guards. · 44 signals shown.

Strongest
Weakest
52-Week Proximity 86
Trendline Break 85
Aroon Oscillator 84

Risk Gates

3 blocking 6 caution

3 guards active, 15 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for LH.